# ë°°ê²½ ìë£Œ: S17 ì¸ìˆ˜ê³µí†µê°ì—¼ë³‘ ì—°êµ¬ (One Health)

**ì„¸ì…˜**: S17 - Emerging Zoonosis Researches for One Health
**ì¼ì‹œ**: 2025ë…„ 10ì›” 28ì¼ (í™”) 09:00-11:00
**ì¥ì†Œ**: Convention Hall 1
**Co-organized**: Korea Zoonosis Research Institute (KoZRI), Jeonbuk National University
**Chair**: Jeong Yoon Lee (Jeonbuk National University) & Jun-Gu Kang (Jeonbuk National University)
**ì¤‘ìš”ë„**: â­â­â­â­â­ (85/100ì ) - **One Health ì—°êµ¬ì í•„ìˆ˜!**

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

ì´ ì„¸ì…˜ì€ **í•œêµ­ì˜ ì£¼ìš” ì¸ìˆ˜ê³µí†µê°ì—¼ë³‘ (Zoonosis)**ê³¼ **One Health ì ‘ê·¼ë²•**ì„ ë‹¤ë£¹ë‹ˆë‹¤. ì „ë¶ëŒ€ Korea Zoonosis Research Institute ì£¼ìµœë¡œ **êµ­ê°€ ì°¨ì›ì˜ zoonosis ëŒ€ì‘ ì „ëµ**ì„ ì œì‹œí•©ë‹ˆë‹¤.

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

- ğŸ¦  **SFTS ë°±ì‹ **: ì¤‘ì¦ì—´ì„±í˜ˆì†ŒíŒê°ì†Œì¦í›„êµ° (ì§„ë“œê¸° ë§¤ê°œ) - í•œêµ­ ì£¼ìš” ìœ„í˜‘
- ğŸ· **ASF ë°±ì‹ **: ì•„í”„ë¦¬ì¹´ë¼ì§€ì—´ë³‘ - í•œêµ­ ì–‘ëˆ ì‚°ì—… ìœ„ê¸°
- ğŸ’Š **AMR Stewardship**: ì–‘ëˆ ì‚°ì—…ì—ì„œ í•­ìƒì œ ì‚¬ìš© ê´€ë¦¬
- ğŸ§¬ **Flavivirus í”Œë«í¼**: SARS-CoV-2 ê¸°ìˆ ì˜ í™•ì¥ ì ìš©
- ğŸ”¬ **Exosome ë©´ì—­**: ì„¸í¬ ì™¸ ì†Œí¬ì²´ ë§¤ê°œ ë³‘ì›ì„±

### ì´ ì„¸ì…˜ì˜ ê³µí†µ í…Œë§ˆ

```
One Health Approach
â”œâ”€ ì¸ê°„-ë™ë¬¼-í™˜ê²½ í†µí•© ê°ì‹œ
â”œâ”€ ë°±ì‹  ê°œë°œ (SFTS, ASF)
â”œâ”€ AMR ê´€ë¦¬ (ì–‘ëˆ)
â”œâ”€ í”Œë«í¼ ê¸°ìˆ  (Flavivirus, SARS-CoV-2)
â””â”€ ë©´ì—­ ê¸°ì „ (Exosome signaling)
```

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (09:00-09:25)

**ì—°ì‚¬**: Jun-Gu Kang (ê°•ì¤€êµ¬)
**ì†Œì†**: Jeonbuk National University (ì „ë¶ëŒ€í•™êµ)
**ì œëª©**: Vaccine development of *Bandavirus dabieense* in mouse and dog models

#### ì—°êµ¬ ë°°ê²½

**Bandavirus dabieense** (êµ¬ëª…: SFTS virus):
- **SFTS** (Severe Fever with Thrombocytopenia Syndrome): ì¤‘ì¦ì—´ì„±í˜ˆì†ŒíŒê°ì†Œì¦í›„êµ°
- **2009ë…„ ì¤‘êµ­ ë°œê²¬**, 2012ë…„ í•œêµ­ ì²« í™•ì§„
- **ì§„ë“œê¸° ë§¤ê°œ** (Haemaphysalis longicornis - ì‘ì€ì†Œí”¼ì°¸ì§„ë“œê¸°)
- **ì¹˜ì‚¬ìœ¨ 10-30%** (í•œêµ­, ì¼ë³¸), ì¤‘êµ­ì€ ~15%

**ë¬¸ì œì **:
- **ì¹˜ë£Œì œ ì—†ìŒ**: ëŒ€ì¦ ìš”ë²•ë§Œ
- **ë°±ì‹  ì—†ìŒ**: ê°œë°œ ì¤‘
- **ë§¤ë…„ ì¦ê°€**: ê¸°í›„ ë³€í™”, ì§„ë“œê¸° ì„œì‹ì§€ í™•ëŒ€

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. SFTS Virus (Bandavirus dabieense)**

**ë¶„ë¥˜**:
- **Family**: Phenuiviridae
- **Genus**: Bandavirus
- **Genome**: Segmented (L, M, S) negative-sense RNA

**êµ¬ì¡°**:
- **Glycoproteins** (Gn, Gc): Envelope, receptor binding
- **Nucleoprotein** (N): RNA ë³´í˜¸, ë©´ì—­ íƒ€ê²Ÿ
- **Polymerase** (L): RNA replication

**ì „íŒŒ ê²½ë¡œ**:
```
ì§„ë“œê¸° (Haemaphysalis longicornis)
  â†“ (ë¬¼ë¦¼)
ì¸ê°„/ë™ë¬¼ (ê°œ, ê³ ì–‘ì´, ì†Œ, ì—¼ì†Œ)
  â†“ (ë°”ì´ëŸ¬ìŠ¤ ì¦ì‹)
ë°œì—´, í˜ˆì†ŒíŒ ê°ì†Œ, ë°±í˜ˆêµ¬ ê°ì†Œ
  â†“
ë‹¤ì¥ê¸° ë¶€ì „ â†’ ì‚¬ë§ (10-30%)
```

**One Health ê´€ì **:
- **ë™ë¬¼**: ë°˜ë ¤ë™ë¬¼ (ê°œ, ê³ ì–‘ì´) ê°ì—¼ â†’ ì‚¬ëŒ ì „íŒŒ?
- **í™˜ê²½**: ì§„ë“œê¸° ì„œì‹ì§€ (ì‚°ë¦¼, í’€ë°­)
- **ì¸ê°„**: ë†ì—… ì¢…ì‚¬ì, ë“±ì‚°ê° ê³ ìœ„í—˜

**2. ë°±ì‹  ê°œë°œ ì „ëµ**

**A. ë¶ˆí™œí™” ë°±ì‹  (Inactivated)**:
```python
# Protocol
1. Virus ë°°ì–‘ (Vero cells)
2. Î²-propiolactone ì²˜ë¦¬ (inactivation)
3. Adjuvant í˜¼í•© (Alum, AS03, etc.)
4. Mouse/Dog immunization
5. Antibody titers (ELISA, neutralization)
6. Challenge (live virus)
```

**B. Subunit ë°±ì‹ **:
- **Gn/Gc glycoproteins**: Receptor binding, neutralizing Ab target
- **Nucleoprotein (N)**: T-cell response

**C. mRNA ë°±ì‹ ** (ìµœì‹ ):
- **LNP-mRNA (Gn, Gc, N)**
- COVID-19 í”Œë«í¼ ì‘ìš©
- ë¹ ë¥¸ ê°œë°œ ê°€ëŠ¥

**3. Mouse Model**

**IFNAR-/- mice** (Interferon receptor knockout):
- **Wild-type**: SFTS virus resistant (interferon ë°˜ì‘)
- **IFNAR-/-**: Susceptible, ì¸ê°„ ì§ˆë³‘ ì¬í˜„
  - ë°œì—´, í˜ˆì†ŒíŒ ê°ì†Œ, ë‹¤ì¥ê¸° ì†ìƒ

**Vaccine efficacy testing**:
```yaml
Groups:
  1. Mock (PBS)
  2. Vaccine (prime-boost, 2-3 weeks)

Challenge:
  - SFTS virus inoculation (10^4-10^6 PFU)
  - Monitor: Weight loss, survival, viral load

Endpoints:
  - Survival rate (%)
  - Viral titer (blood, organs) - qRT-PCR
  - Pathology (H&E, IHC)
```

**4. Dog Model** â­

**ì™œ ê°œ?**
- **Natural host**: ê°œë„ SFTS ê±¸ë¦¼ (ì•¼ì™¸ ì§„ë“œê¸°)
- **ì‚¬ëŒê³¼ ìœ ì‚¬**: ì¦ìƒ, ë©´ì—­ ë°˜ì‘
- **Zoonotic transmission**: ê°œ â†’ ì‚¬ëŒ ì „íŒŒ ë³´ê³ 

**Dog vaccination**:
```yaml
Protocol:
  - Healthy dogs (Beagle)
  - Vaccine IM (2-3 doses)
  - Antibody monitoring (weeks 0, 2, 4, 8)

Safety:
  - Adverse events (injection site, ë°œì—´)
  - Blood chemistry (ê°„, ì‹ ì¥)

Efficacy:
  - Neutralizing antibody titer
  - T-cell response (IFN-Î³ ELISPOT)
  - Challenge (experimental or field trial)
```

**5. ì˜ˆìƒ ê²°ê³¼**

**Mouse**:
- **Survival**: 0% (Mock) vs. 80-100% (Vaccine)
- **Viral load**: 10â¶ â†’ 10Â² copies/mL
- **Antibody**: Neutralizing titer >1:320

**Dog**:
- **Seroconversion**: 100%
- **Neutralizing Ab**: Detectable at week 2, peak week 4
- **Safety**: Well-tolerated

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**One Health ì‹¤í—˜ì‹¤ ê´€ì **:

**1. Zoonotic Virus Research**:
- **Biosafety**: BSL-3 facility í•„ìš”
- **Animal models**: ìœ¤ë¦¬ ìŠ¹ì¸, ì‹œì„¤
- **Field surveillance**: ì§„ë“œê¸°, ë™ë¬¼, ì‚¬ëŒ ìƒ˜í”Œë§

**2. Vaccine Development Pipeline**:
```
1. Antigen selection (Gn/Gc/N)
2. Expression system (mammalian, E. coli)
3. Adjuvant screening
4. Immunogenicity (small animals)
5. Efficacy (challenge model)
6. Safety (toxicology)
7. GMP production
8. Clinical trials (Phase I/II/III)
```

**3. Serological Assays**:
| Assay | Purpose |
|-------|---------|
| **ELISA** | Antibody quantification |
| **Neutralization (PRNT)** | Functional antibody |
| **ELISPOT (IFN-Î³)** | T-cell response |
| **Flow cytometry** | Cell subsets (CD4/CD8) |

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Bunyavirales (Phenuiviridae)**
- **Segmented genome**: L, M, S
- **Ambisense**: S segment codes both strands
- **Vector-borne**: ì§„ë“œê¸°, ëª¨ê¸°

**2. IFNAR-/- Mouse**
- **Type I IFN**: IFN-Î±/Î²
- **Receptor**: IFNAR1/IFNAR2
- **Knockout**: Viral infection susceptible
- **Use**: Vaccine/drug testing

**3. Neutralizing Antibodies**
- **PRNT** (Plaque Reduction Neutralization Test)
- **Titer**: 50% reduction (PRNT50), 90% (PRNT90)
- **Correlate of protection**: >1:40-80

#### ì˜ˆìƒ ì§ˆë¬¸

1. "**ì‚¬ëŒ ì„ìƒ ì‹œí—˜** ê³„íš? Phase I ì‹œì‘ ì‹œê¸°?"
2. "**Dog-to-human transmission** ì¦ê±°? ë°±ì‹ ìœ¼ë¡œ ì°¨ë‹¨ ê°€ëŠ¥?"
3. "**Cross-protection**: ë‹¤ë¥¸ Bandavirus (Heartland virus, etc.)ì—ë„ íš¨ê³¼?"
4. "**Mass production**: GMP facility, capacity?"
5. "**Adjuvant selection**: Alum vs. AS03 vs. CpG? ìµœì ì€?"

---

### ğŸ”¹ ë°œí‘œ 2 (09:25-09:50)

**ì—°ì‚¬**: Jung Hyang Sur (ì„œì •í–¥)
**ì†Œì†**: Komipharm International Co., Ltd. (ê¸°ì—…)
**ì œëª©**: Safety and protective efficacy of the live attenuated ASFV-G-Î”I177L/Î”LVR vaccine in pregnant sows and growing pigs

#### ì—°êµ¬ ë°°ê²½

**ASF (African Swine Fever)**: ì•„í”„ë¦¬ì¹´ë¼ì§€ì—´ë³‘
- **2019ë…„ í•œêµ­ ë°œìƒ**, ì´í›„ ì§€ì† ë°œìƒ
- **ì¹˜ì‚¬ìœ¨ 100%** (ê¸‰ì„±í˜•)
- **ë°±ì‹  ì—†ìŒ** (ìƒìš©í™”ëœ ê²ƒ)
- **ê²½ì œì  ì†ì‹¤**: ìˆ˜ì²œì–µ ì›

**ASFV-G-Î”I177L/Î”LVR**:
- **Live attenuated vaccine**: ì•½ë…í™” ìƒë°±ì‹ 
- **Deletion**: I177L (ë©´ì—­ ì–µì œ), LVR (virulence region)

#### ì˜ˆìƒ ë‚´ìš©

**1. ASF Virus**:
- **Large DNA virus** (~190 kb)
- **ë³µì¡í•œ genome**: 150-200 ORFs
- **Immune evasion**: ë‹¤ì–‘í•œ ë©´ì—­ ì–µì œ ìœ ì „ì

**2. Vaccine Strategy**:
```
ASFV Georgia 2007 (virulent)
  â†“
I177L deletion (ë©´ì—­ ì–µì œ ì œê±°)
  â†“
LVR deletion (virulence ê°ì†Œ)
  â†“
ASFV-G-Î”I177L/Î”LVR (attenuated)
```

**3. Safety in Pregnant Sows**:
- **Critical**: ì„ì‹ ëˆ ì•ˆì „ì„± (ìœ ì‚°, ê¸°í˜• ìš°ë ¤)
- **Results**: No abortion, healthy piglets

**4. Efficacy in Growing Pigs**:
- **Protection**: 100% survival vs. virulent challenge
- **Antibody**: Long-term (>6 months)

**5. Challenges**:
- **DIVA** (Differentiating Infected from Vaccinated Animals): í•„ìš”
- **Reversion**: ì•½ë…í™” ë°”ì´ëŸ¬ìŠ¤ì˜ ë…ì„± ë³µê·€ ê°€ëŠ¥ì„±
- **Scale-up**: ëŒ€ëŸ‰ ìƒì‚°

---

### ğŸ”¹ ë°œí‘œ 3 (09:50-10:15)

**ì—°ì‚¬**: Kwang-Won Seo (ì„œê´‘ì›)
**ì†Œì†**: Chungbuk National University (ì¶©ë¶ëŒ€í•™êµ)
**ì œëª©**: Development of antimicrobial stewardship model in swine production for reducing zoonosis

#### ì˜ˆìƒ ë‚´ìš©

**1. Antimicrobial Use in Swine**:
```yaml
Korea:
  - Antibiotics use (tons/year): High
  - Purpose: Growth promotion, disease prevention

Problems:
  - AMR emergence (E. coli, Salmonella, MRSA)
  - Environmental contamination (manure, water)
  - Zoonotic transmission (farm â†’ human)
```

**2. Antimicrobial Stewardship**:
```
Principles:
  1. Surveillance (AMR monitoring)
  2. Prescription guidelines (veterinary oversight)
  3. Alternatives (probiotics, vaccines, hygiene)
  4. Education (farmers)

Implementation:
  - Farm-level interventions
  - Regional coordination
  - Policy (ban on growth promoters)
```

**3. Model Development**:
- **Data collection**: Antibiotic use, AMR prevalence
- **Intervention**: Reduce use by 30-50%
- **Outcomes**: AMR â†“, productivity maintained

**4. Zoonosis Reduction**:
- **Human colonization**: Farmer MRSA carriage â†“
- **Foodborne**: Pork AMR bacteria â†“

---

### ğŸ”¹ ë°œí‘œ 4 (09:50-10:15)

**ì—°ì‚¬**: Jun-Gyu Park (ë°•ì¤€ê·œ)
**ì†Œì†**: Chonnam National University (ì „ë‚¨ëŒ€í•™êµ)
**ì œëª©**: Application of reverse genetics technology in SARS-CoV-2 vaccine development and its extension to flavivirus platforms

#### ì˜ˆìƒ ë‚´ìš©

**1. Reverse Genetics**:
```
Viral genome (cDNA/BAC)
  â†“
Transfection into cells
  â†“
Recombinant virus rescue
  â†“
Attenuation mutations
  â†“
Live attenuated vaccine candidate
```

**2. SARS-CoV-2 Applications**:
- **Codon deoptimization**: Virus ì•½ë…í™”
- **Deletion mutants**: nsp1, ORF3a, ORF7a ì œê±°

**3. Flavivirus Extension**:
- **Platform**: JEV (Japanese Encephalitis Virus)
  - SA14-14-2 (live attenuated strain)
- **Chimeric viruses**: JEV backbone + other flavivirus E protein
  - Dengue, Zika, West Nile ë°±ì‹ 

**4. Advantages**:
- **Rapid**: Genome editing â†’ 2-4 weeks
- **Precise**: Specific mutations
- **Scalable**: Cell culture production

---

### ğŸ”¹ ë°œí‘œ 5 (10:40-11:05)

**ì—°ì‚¬**: Do-Kyun Kim (ê¹€ë„ê· )
**ì†Œì†**: Jeonbuk National University (ì „ë¶ëŒ€í•™êµ)
**ì œëª©**: Exosome-mediated signaling in mast cell-driven immune pathologies

#### ì˜ˆìƒ ë‚´ìš©

**1. Mast Cells**:
- **Allergic responses**: IgE-mediated degranulation
- **Innate immunity**: Pattern recognition
- **Exosome release**: Inflammatory signals

**2. Exosome Cargo**:
- **Cytokines**: IL-4, IL-13, TNF-Î±
- **Proteases**: Tryptase, chymase
- **miRNA**: Immune regulation

**3. Zoonosis Connection**:
- **Parasitic infections**: Helminth, protozoa
- **Tick-borne diseases**: SFTS, Lyme
- **Mast cell activation** â†’ Exosome release â†’ Pathology

**4. Therapeutic Targets**:
- **Exosome biogenesis inhibitors**
- **Mast cell stabilizers**

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### S17ì˜ í•µì‹¬ ë©”ì‹œì§€

**"One HealthëŠ” ì¸ê°„-ë™ë¬¼-í™˜ê²½ì˜ í†µí•© ì ‘ê·¼ì´ë‹¤"**

| ë°œí‘œ | ì£¼ì œ | One Health ì¸¡ë©´ |
|------|------|----------------|
| **Kang** | SFTS ë°±ì‹  | ì§„ë“œê¸°-ë™ë¬¼-ì‚¬ëŒ |
| **Sur** | ASF ë°±ì‹  | ë¼ì§€-ì‚°ì—…-ì‹ëŸ‰ì•ˆë³´ |
| **Seo** | AMR stewardship | ë†ì¥-í™˜ê²½-ì‚¬ëŒ |
| **Park** | Flavivirus í”Œë«í¼ | ëª¨ê¸°-ë™ë¬¼-ì‚¬ëŒ |
| **Kim** | Exosome ë©´ì—­ | ê¸°ìƒì¶©-ë©´ì—­-ì§ˆë³‘ |

### í†µí•© ê´€ì 

```yaml
One Health Triangle:
  Human Health:
    - SFTS í™˜ì ì¹˜ë£Œ
    - Zoonotic AMR ê°ì—¼

  Animal Health:
    - ê°€ì¶• ë°±ì‹  (ASF, SFTS)
    - í•­ìƒì œ ì‚¬ìš© ê´€ë¦¬

  Environmental Health:
    - ì§„ë“œê¸°/ëª¨ê¸° ì„œì‹ì§€ ê´€ë¦¬
    - í•­ìƒì œ í™˜ê²½ ì˜¤ì—¼ ê°ì†Œ

Intersection:
  - Integrated surveillance
  - Vaccine development
  - AMR control
  - Climate adaptation
```

---

## ğŸ“š ì‚¬ì „ ì½ê¸°

### í•„ìˆ˜
1. **SFTS Virus Review (2024)**: Pathogenesis and vaccine development
2. **ASF Vaccine (2024)**: Live attenuated vaccines
3. **AMR in Livestock (2024)**: Stewardship programs

### ì¶”ì²œ
4. **One Health Framework (WHO, 2023)**
5. **Reverse Genetics (2023)**: Flavivirus platforms

---

## ğŸ¤ Top 5 Questions

1. **[Kang]** "SFTS ë°±ì‹  ì‚¬ëŒ ì„ìƒ ì‹œí—˜ ê³„íš? Phase I ì‹œì‘?"
2. **[Sur]** "ASF ë°±ì‹  DIVA strategy? ì•¼ìƒ ê°ì—¼ vs. ë°±ì‹  êµ¬ë³„?"
3. **[Seo]** "AMR Stewardship ê²½ì œì„±? ë†ê°€ ìˆ˜ìš©ì„±?"
4. **[Park]** "JEV í”Œë«í¼ìœ¼ë¡œ pan-flavivirus vaccine ê°€ëŠ¥?"
5. **[Kim]** "Exosome inhibitors as anti-allergic therapy?"

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

1. **Jun-Gu Kang** (ì „ë¶ëŒ€) â­â­â­ - êµ­ë‚´, SFTS ì „ë¬¸ê°€
2. **Kwang-Won Seo** (ì¶©ë¶ëŒ€) â­â­ - AMR stewardship
3. **Jun-Gyu Park** (ì „ë‚¨ëŒ€) â­â­ - Reverse genetics

---

**ì˜ˆìƒ í•™ìŠµ ì„±ê³¼**:
âœ… SFTS, ASF ë°±ì‹  ìµœì‹  ì—°êµ¬
âœ… AMR stewardship ì „ëµ
âœ… Flavivirus í”Œë«í¼ ê¸°ìˆ 
âœ… One Health í†µí•© ì ‘ê·¼ë²•

**One Health ì—°êµ¬ì/ìˆ˜ì˜í•™ í•„ìˆ˜!** ğŸ¾
